Reversible sulfasalazine-induced granulomatous hepatitis

Albert Namias, Rakesh Bhalotra, Mark Donowitz

Research output: Contribution to journalArticle

Abstract

Sulfasalazine, a drug common in the treatment of inflammatory bowel disease, may cause liver damage. We present a patient with documented granulomatous hepatitis which resolved on liver biopsy 6 weeks after discontinuation of the drug.

Original languageEnglish (US)
Pages (from-to)193-198
Number of pages6
JournalJournal of clinical gastroenterology
Volume3
Issue number2
DOIs
StatePublished - Jun 1981
Externally publishedYes

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Reversible sulfasalazine-induced granulomatous hepatitis'. Together they form a unique fingerprint.

  • Cite this